TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06459401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Propulsion Neuroprosthesis
Description: A neuroprosthesis is a textile-based surface neurostimulation system worn on the waist and paretic lower limb that delivers neurostimulation assistance via electroconductive pads placed on the skin over the target muscles. The neuroprosthesis provides dorsiflexor stimulation during swing phase for foot clearance and plantarflexor stimulation during stance phase for propulsion, delivered synchronously based on integrated sensors detecting the wearer's gait pattern.
Study: NCT05653518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim X2 with Control-IQ Technology
Description: FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensor augmented pump (SAP) therapy
Description: Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's personal insulin pump
Study: NCT06408428

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PANAXIUM MicroECoG
Description: The PANAXIUM microelectrode ( 4x2 cm, 6 micron-thick electrode comprising 128 electrodes (28 500 µm electrodes, 96 30 µm diameter microelectrodes organized as tetrodes and 4 reference electrodes) will be placed on the cortical surface and repositioned every 90 seconds to sample the entire exposed brain surface. During the cortical electrical stimulation mapping phase, the electrode will be left at the edge of the field to detect epileptic discharges induced by stimulation. After resection, a new recording of the residual cortical surface will be made to check for persistent electrical anomalies. In the last 10 patients, the Panaxium microECoG will be compared with a macro-electrode for clinical use.
Study: NCT06539286

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Irradiation
Description: three different laser wavelengths will be used

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Irradiation
Description: three different laser wavelengths will be used

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Irradiation
Description: three different laser wavelengths will be used

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser Irradiation
Description: three different laser wavelengths will be used
Study: NCT05719129

Intervention type: BEHAVIORAL
Intervention: Date With Destiny (DWD) Seminar
Description: 6 days of immersive seminar
Study: NCT04068155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DaRT- Diffusing Alpha-emitters Radiation Therapy
Description: Seed(s) loaded with Radium-224 for local intratumoral irradiation with the destructive power of alpha particles
Study: NCT05524714

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: solubilized Xanthohumol low dose
Description: single administration of 2 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol and 2 soft gelatine capsules containing only micelles

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: solubilized Xanthohumol high dose
Description: single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: native Xanthohumol low dose
Description: single administration of 2 hard gelatine capsules each containing 43 mg native Xanthohumol and 2 hard gelatine capsules containing silicon dioxide

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: native Xanthohumol high dose
Description: single administration of 4 hard gelatine capsules each containing 43 mg native Xanthohumol
Study: NCT06290739

Intervention type: PROCEDURE
Intervention: lymph nodes dissection
Description: Whether lymph nodes dissection should be performed on curative-intent hepatectomy for intrahepatic cholangiocarcinoma is still debated.
Study: NCT06398080

Intervention type: DRUG
Intervention: aflibercept 8 mg
Description: No intervention will be provided to study patients. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and following approved clinical guidelines.

Intervention type: DRUG
Intervention: aflibercept 8 mg
Description: No intervention will be provided to study patients. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and following approved clinical guidelines.

Intervention type: DRUG
Intervention: aflibercept 8 mg
Description: No intervention will be provided to study patients. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and following approved clinical guidelines.

Intervention type: DRUG
Intervention: aflibercept 8 mg
Description: No intervention will be provided to study patients. Any treatment decision, including the decision for aflibercept 8 mg treatment, is at the discretion of the attending physician, made in accordance with his/her experience and following approved clinical guidelines.
Study: NCT05756985

Intervention type: PROCEDURE
Intervention: Specimen Collection
Description: Collect and preserve glioblastoma tissue for exploratory analyses to generate hypotheses for future studies.
Study: NCT05495425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-12Y gel
Description: NPC-12Y gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPC-12Y placebo gel
Description: NPC-12Y placebo gel is applied twice a day for 12 weeks. After the double-blind evaluation period, NPC-12Y gel is applied twice a day for 52 weeks.
Study: NCT05980858

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beta-hydroxybutyrate
Description: Each subject receive Beta-hydroxybutyrate 300mg/kg x 3 for five days. After the treatment period effect variables will be examined.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beta-hydroxybutyrate
Description: Each subject receive Beta-hydroxybutyrate 300mg/kg x 3 for five days. After the treatment period effect variables will be examined.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Each subject receive a placebo drink 3 x day for five days. After the treatment period effect variables will be examined.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Each subject receive a placebo drink 3 x day for five days. After the treatment period effect variables will be examined.
Study: NCT05120752

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FODMAP diet
Description: all participants need to follow a low FODMAP diet, the information will be given by a trained dietitian
Study: NCT05425277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reciprocal Intervention Teaching (RIT)
Description: RIT is a relatively straightforward, brief NDBI. It employs four simple strategies to target motor imitation and initiating joint attention during play: (1) contingent imitation of the child's verbal and nonverbal behavior, (2) linguistic mapping, (3) direct elicitation of object and gesture imitation following the child's interest, and (4) contingent reinforcement. It has been used at low intensities (e.g., 1-3 hours per week) over short periods of time (e.g., 10-12 weeks) to produce robust changes in pivotal social-communicative skills. RIT is easy to learn and can be implemented with fidelity by undergraduate-level therapists with limited backgrounds in ASD, as well as by caregivers and siblings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Routines
Description: The Routines webinar was adapted from a web-based tutorial developed by PI Stone and colleagues (Ibanez et al., 2018). The webinar covers topics such as why everyday routines are important, especially for children with ASD, specific steps for increasing children's participation in routines, and how to use strategies such as visual supports to clarify expectations, and provides numerous video examples of caregivers using different strategies. Providers are also given access to a video library of caregivers using the Daily Routines strategies with their children, as well as a workbook to use with families during treatment.
Study: NCT06360523

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AI modal
Description: The MRI image will be reviewed by radiologist and AI model(s) respectively. The urologist will combine the results of the two approaches to optimize the biopsy strategy which is expected to result in more accurate diagnosis.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard review
Description: The MRI image will be reviewed by radiologist.
Study: NCT06375837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: an alkasite-based restorative material
Description: Cention N

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hybrid resin composite
Description: Gradia Direct Anterior

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a highly filled flowable resin composite
Description: G-aenial Universal Flo
Study: NCT06349525

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: telescopic overdenture
Description: Maxillary implant supported telescopic overdenture

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Locator overdenture
Description: Maxillary implant supported locator overdenture
Study: NCT04923906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib
Description: Aumolertinib 110 mg QD in combination with pemetrexed (500 mg/m2) plus cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of every 21-day cycles up to 4\~6 cycles, followed by Aumolertinib 100mg QD with pemetrexed maintenance (500 mg/m2) on Day 1 of every 21-day cycles.~Dose may be reduced to allow for the management of investigational drug related toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Aumolertinib
Description: Placebo Aumolertinib 110 mg QD Dose may be reduced to allow for the management of investigational drug related toxicity.
Study: NCT06007209

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Pressure Point
Description: Compression of the subclavian artery against the 1st rib and of the common femoral artery against the pelvis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Pressure Point
Description: Compression of the subclavian artery against the 1st rib and of the common femoral artery against the pelvis.
Study: NCT05353491

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology assisted Thinking Healthy Program (THP-TA)
Description: A technology adapted version of the Thinking Healthy Program (THP) delivered by peers using multimedia android based app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Thinking Healthy Program
Description: This intervention paper-based manual delivered by lady health workers ie government employed community health workers with health training background.
Study: NCT05848687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO) or naso-gastrically (NG) or intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG asparaginase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Taken PO or NG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO or NG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV, IM or PO
Study: NCT05626361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dysphagia training
Description: Training using PowerPoint and simulation. Training includes anatomy physiology, screening and management sections. Simulation will be used for practice. Reading material will also be provided

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reading material
Description: Reading material provided to nurses covering knowledge related to nursing evaluation and caring for dysphagia patients
Study: NCT00548821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT06571786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren lipid microsphere
Description: Definity (Lantheus Medical Imaging, N Billerica, MA) in 25 mL of saline infused for up to 6 minutes
Study: NCT05848687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Will be administered at 15 mcg/m2/day for 28 days following induction and reinduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziftomenib
Description: 3+3 dose escalation will be done. Dose level 1 will start at 75% of the adult recommended phase two dosing which has been established in phase I studies. Based on tolerability, we will either de-escalate to 50% RP2D (dose level -1) or escalate to 100% RP2D
Study: NCT05049460

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta Burst Stimulation
Description: Four sessions of theta burst stimulation (TBS) at 120 % RMT and comprising 7200 pulses, given with functional targeting.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham TMS
Description: Four sessions of sham TMS, done using the A/P MagVenture coil, with subject's head separated from the coil by foam padding.
Study: NCT05581199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Study: NCT05852496

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin D
Description: vitamin D supplement in cancer patients which receive taxane drugs with vit D deficiency and complaining from Peripheral neuropathy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: vitamin D supplement in cancer patients which receive taxane drugs with vit D deficiency and complaining from Peripheral neuropathy.
Study: NCT04824846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated back pain module (IBPM)
Description: All Ambulance drivers will be screening with the Proforma to determine their low back pain symptoms. Those workers who are diagnosed with mechanical back pain during the 12 months fulfill a self-report quality of life questionnaire (SF-36). Then Integrated back pain module (IBPM) will be delivered to them after the introduction course conducted for 1 day and then the intervention will last for 6 months. Research staff will explain how to operate and use the module. Subjects must comply with all the care and prevention guidelines of the research module so that it achieves the expected results. They also need to complete the checklist provided in the Edmodo software via their respective smartphones.

Intervention type: OTHER
Group type: OTHER
Intervention: Health Educational Pamphlet.
Description: In Health Educational Pamphlet (HEP) sessions, Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
Study: NCT05581199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Study: NCT05550233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: drug-coated balloon
Description: drug-coated balloon in big de novo coronary disease

Intervention type: DEVICE
Group type: OTHER
Intervention: drug-coated balloon
Description: drug-coated balloon in big de novo coronary disease
Study: NCT05581199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Batoclimab 340 mg SC weekly
Description: Batoclimab is a fully human anti-neonatal fragment crystallizable receptor (FcRn) monoclonal antibody
Study: NCT05401617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional information via the computerized tool
Description: additional information delivered via the computerized tool
Study: NCT06306898

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Intubation
Description: Ventilation with an endotracheal tube

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Intubation
Description: Ventilation with an endotracheal tube

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Intubation
Description: Ventilation with an endotracheal tube

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal tube
Description: Ventilation with an laryngeal tube

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal tube
Description: Ventilation with an laryngeal tube

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal tube
Description: Ventilation with an laryngeal tube

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask
Description: Ventilation with an laryngeal mask

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask
Description: Ventilation with an laryngeal mask

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask
Description: Ventilation with an laryngeal mask

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I-Gel-Laryngeal Mask
Description: Ventilation with an I-Gel-laryngeal mask

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I-Gel-Laryngeal Mask
Description: Ventilation with an I-Gel-laryngeal mask

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I-Gel-Laryngeal Mask
Description: Ventilation with an I-Gel-laryngeal mask
Study: NCT05680519

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: theory of planned behaviour, foot-in-the-door technique, and self-determination theory intervention
Description: The participants will also be asked to choose the goal that they consider easiest to achieve and encouraged to quit health-risk behaviours. The research assistant will assist in achieving the participant's health-related goals by sending WhatsApp/WeChat messages or via telephone calls once per week for the first 6 months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The participants will be simply advised to modify their health-risk behaviours and/or adopt a healthy lifestyle practice. In addition, the research assistant will send regular SMS messages to the participants at a similar frequency to the intervention group, but these messages will contain only general health advice.
Study: NCT05582889

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Intervention
Description: Participants receive a Fitbit activity tracker and the free Fitbit smartphone app. A trained health coach provides technical support to set up and use the Fitbit and app. The health coach also provides motivational counseling to help participants to gradually increase the number of steps per day during the 12-weeks.
Study: NCT05581199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo SC
Study: NCT05582889

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit Intervention
Description: Participants receive a Fitbit activity tracker and the free Fitbit smartphone app. A trained health coach provides technical support to set up and use the Fitbit and app. The health coach also provides motivational counseling to help participants to gradually increase the number of steps per day during the 12-weeks.
Study: NCT06016205

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intrathecal morphine injection
Description: Patients will receive intrathecal 200 microgram morphine immediately before induction of general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound guided PECS2 block
Description: ultrasound guided PECS2 block will be performed with 30 ml bupivacaine 0.25%